Physician profile
Kevin T DO
NPI 1104078880
$29,233.56
in general payments reported to CMS, 2019-2025
27 companies · $733 in 2025
The $733 reported for 2025 was more than what 78% of Neuromuscular Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $128).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $461 · 2021: $455 · 2022: $3,514 · 2023: $6,384 · 2024: $18K · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $18K · Food and Beverage: $4,369 · Consulting Fee: $2,000 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $18,308.93 |
| Food and Beverage | $4,369.20 |
| Consulting Fee | $2,000.00 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $26,069.98 | 2019-2025 | Xeomin |
| Abbvie INC. | $705.08 | 2023-2025 | Botox |
| Solta Medical, A Division of Bausch Health US, LLC | $612.12 | 2022-2025 | Clear+Brilliant |
| Allergan, INC. | $357.67 | 2020-2022 | |
| Janssen Biotech, INC. | $326.35 | 2022-2025 | Darzalex, Imbruvica, Talvey |
| Revance Therapeutics, INC. | $231.59 | 2024-2025 | Daxxify |
| Aveo Pharmaceuticals, INC. | $173.31 | 2022-2024 | Fotivda |
| Takeda Pharmaceuticals U.S.A., INC. | $94.40 | 2023 | Alunbrig |
| Amneal Pharmaceuticals LLC | $78.54 | 2019-2023 | Neulasta, Avastin, Neupogen |
| Galderma Laboratories, L.P. | $78.06 | 2021-2024 | |
| Octapharma USA, INC. | $74.30 | 2021-2023 | Panzyga |
| Servier Pharmaceuticals LLC | $52.86 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $49.81 | 2024 | |
| Organon LLC | $39.34 | 2022-2023 | Ontruzant |
| Janssen Pharmaceuticals, INC | $35.50 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $35.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $34.77 | 2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $32.61 | 2025 | |
| Daiichi Sankyo INC. | $25.76 | 2025 | Datroway |
| Merck Sharp & Dohme LLC | $24.69 | 2022 | |
| Stimwave Technologies Incorporated | $18.85 | 2020 | |
| Deciphera Pharmaceuticals INC. | $18.78 | 2021 | |
| Coherus Oncology, INC. | $17.97 | 2022 | |
| Kyowa Kirin, INC. | $17.75 | 2023 | Poteligeo |
| Mirati Therapeutics, INC. | $14.67 | 2023 | Krazati |
| Foundation Medicine, INC. | $13.80 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.